LinKinVax is developing a unique and innovative vaccine platform that accelerates the availability of safe, effective and scalable vaccines, based on the work of the VRI (Vaccine Research Institute), a French laboratory of excellence created in 2011. This vaccine platform called DC Targeting is universal, and adaptable to the evolutions and mutations of the target pathogens.
Five vaccines will be proposed to the market within five years, including a vaccine already in clinical trial on HIV in 2021, and two vaccines which will be in clinical phase in 2022 (SARS-CoV-2, HPV-related cancer). On the other hand, LinKinVax supports upstream research to be able to adapt its platform to new pathogens.
Resulting from the association of leading French scientists and entrepreneurs, LinKinVax benefits from a portfolio of 13 patent families extended internationally and from a close partnership with the VRI laboratory of excellence.
For more information, please visit https://:www.linkinvax.com
Under the responsibility of the Director of CMC activities, you will be integrated to the project management team of Manufacturing and Controls activities in support of development of the drug products of LinKinVax within a completely outsourced environment.
You will contribute by your operational expertise to ensure the effective and efficient delivery of all operational aspects of one or more CMC activities program through all phases of the drug development in accordance with the appropriate quality standards including ICH/GMP and applicable regulations. The suitable candidate achieves this by delivering high quality study management support and other high value services to enable team and project success.